Navigation Link

1215 South Walnut Ave.
Demopolis, AL 36732 mapmap

Access to Care: 800.239.2901

Post-Traumatic Stress Disorder
Basic Information
Introduction to Trauma and Stressor-Related DisordersSigns and Symptoms of Trauma and Stressor-Related DisordersDiagnostic Descriptions of Trauma and Stressor-Related DisordersWhat Causes the Symptoms of Trauma-Related Disorders? Treatment of Trauma, PTSD, Abuse and Other Stressor-Related Disorders Conclusion, Resources and ReferencesDealing with the Effects of Trauma - A Self-Help Guide
More InformationLatest NewsQuestions and AnswersVideosLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Depression & Related Conditions
Addictions: Alcohol and Substance Abuse
Dissociative Disorders

Massed Prolonged Exposure Tx Tied to More PTSD Improvement

HealthDay News
Updated: Jan 25th 2018

new article illustration

THURSDAY, Jan. 25, 2018 (HealthDay News) -- Prolonged exposure therapy administered as mass therapy is associated with a greater reduction in posttraumatic stress disorder (PTSD) symptom severity than a minimal-contact control (MCC), according to a study published in the Jan. 23/30 issue of the Journal of the American Medical Association.

Edna B. Foa, Ph.D., from the University of Pennsylvania in Philadelphia, and colleagues conducted a randomized trial involving 370 military personnel with PTSD who had returned from Iraq, Afghanistan, or both. Participants were assigned to receive prolonged exposure therapy (cognitive behavior therapy involving exposure to trauma memories/reminders, administered as massed therapy [10 sessions over two weeks] or spaced therapy [10 sessions over eight weeks]; 110 and 109 participants, respectively); present-centered therapy (PCT; non-trauma focused therapy involving identifying/discussing daily stressors; 107 participants); or MCC (telephone calls from therapists; 40 participants)

The researchers found that at two weeks after treatment, the mean PTSD Symptom Scale-Interview (PSS-I) score was 17.62 for massed therapy (mean decrease from baseline, 7.13) and 21.41 for MCC (mean decrease, 3.43; difference in decrease, 3.7; 95 percent confidence interval, 0.72 to 6.68). The mean PSS-I score was 18.03 for spaced therapy (decrease, 7.29; difference versus massed therapy, 0.79). At 12 weeks after treatment, the mean PSS-I score was 18.88 for massed therapy (decrease, 6.32) and 18.34 for spaced therapy (decrease, 6.97; difference, 0.55). The PSS-I scores for PCT were 18.65 (decrease, 7.31; difference in decrease versus spaced therapy, 0.1 [95 percent confidence interval, −2.48 to 2.27]) at post-treatment.

"The reductions in PTSD symptom severity with all treatments were relatively modest, suggesting that further research is needed to determine the clinical importance of these findings," the authors write.

Abstract/Full Text
Editorial (subscription or payment may be required)